Top

Published in:

01-05-2015 | Original Communication

Validation of the multimodal assessment of capacities in severe dementia: a novel cognitive and functional scale for use in severe dementia

Authors: Sloane Heller, Carolina Mendoza Rebolledo, Carmen Rodríguez Blázquez, Laura Carrasco Chillón, Almudena Pérez Muñoz, Irene Rodríguez Pérez, Pablo Martínez-Martín

Published in: Journal of Neurology | Issue 5/2015

Abstract

The multimodal assessment of capacities in severe dementia (MAC-SD), a novel cognitive and functional assessment, was developed for use with patients with severe dementia. Its psychometric attributes were examined in a unicenter, open, observational study. The MAC-SD along with the Spanish language Severe Mini Mental Exam were administered to 103 patients with a diagnosis of severe dementia. Psychometric analyses were performed to determine acceptability, reliability, validity, and responsiveness. As a whole, the MAC-SD sections showed no floor effects, satisfactory internal consistency, reproducibility, construct validity, precision, and sensitivity to change. The MAC-SD performed as a useful, valid, and potentially responsive tool to measure cognition and functioning in the most advanced stages of dementia.

Available only for authorised users

Reisberg B (2007) Global measures: utility in defining and measuring treatment response in dementia. Int Psychogeriatr 19:421–456CrossRefPubMed

Bonnel WB (1996) Not gone and not forgotten: a spouse’s experience of late-stage Alzheimer’s disease. J Psychosoc Nurs Ment Health Serv 34:23–27PubMed

Schmitt FA (1997) SIB: current validity and assessment of longitudinal change in AD. Alzheimer Dis Assoc Dis 11:S51–S56CrossRef

Voisin T, Reynish E, Portet F, Feldman H, Vellas B (2004) What are the treatment options for patients with severe AD? CNS Drugs 18:575–583CrossRefPubMed

Robert P, Ferris S, Gauthier S, Ihl R, Winblad B, Tennigkeit F (2010) Review of AD Scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? Alzheimers Res Ther 22:24CrossRef

Schmitt FA, Cragar D, Ashford JW, Reisberg B, Ferris S, Möbius HJ, Stöffler A (2002) Measuring cognition in advanced AD for clinical trials. J Neural Transm Suppl 62:135–148CrossRefPubMed

Holthoff VA, Ferris S, Ihl R, Robert P, Winblad B, Gauthier S, Sternberg K, Tennigkeit F (2011) Validation of the relevant outcomes scale for Alzheimer’s disease: a novel multidomain assessment for daily medical practice. Alzheimers Res Ther 3:27PubMedCentralCrossRefPubMed

Olazarán J, Agüera-Ortiz L, Osorio RS, León-Salas B, Dobato JL, Cruz-Orduña I, González B, Valentí M, Gil-Ruiz N, Frades B, Ramos García MI, Martínez-Martín P (2012) Promoting clinical research in advanced dementia: early clinical results of the Alzheimer Center Reina Sofia Foundation. J Alzheimers Dis 28:211–222PubMed

Martínez-Martín P, Avila J, AD Research Unit Investigators (2010) Alzheimer Center Reina Sofia Foundation: fighting the disease and providing overall solutions. J Alzheimers Dis 21:337–348PubMed

10.

Auer S, Reisberg B (1997) The GDS/FAST staging system. Int Psychogeriatr 9:167–171CrossRefPubMed

11.

Buiza C, Navarro A, Díaz-Orueta U, González MF, Alaba J, Arriola E, Hernández C, Zulaica A, Yanguas JJ (2011) Short evaluation of cognitive state in advanced stages of dementia: preliminary results of the Spanish validation of the Severe-Mini Mental State Examination. Rev Esp Geriatr Geruntol 46:131–138CrossRef

12.

Mokkik L, Terwee C, Knol D, Stratford P, Alonso J, Patrick D, Bouter L, de Vet H (2010) The COSMIN checklist for evaluating the methodological quality of studies on measurement of properties: a clarification of its content. BMC Med Res Methodol 10:22CrossRef

13.

Martinez-Martin P, Frades-Payo B, Agüera-Ortiz L, Ayuga-Martinez A (2012) A short scale for evaluation of neuropsychiatric disorders in Parkinson’s disease: first psychometric approach. J Neuro 259:2299–2308CrossRef

14.

Martinez Martin P, Forjaz MJ (2012) How to evaluate validation data. In: Sampaio C, Goetz CG, Schrag A (eds) Rating scales in Parkinson’s disease. Oxford University Press, Oxford, pp 16–41CrossRef

15.

Ware JE, Gandek B (1998) Methods for testing data quality, scaling assumptions, and reliability: the IQOLA Project approach. International quality of life assessment. J Clin Epidemiol 51:945–952CrossRefPubMed

16.

Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martínez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, Singer C, Tilley BC, Huang J, Stebbins GT, Goetz CG (2013) Expanded and independent validation of the Movement Disorder Society—Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). J Neurol 260:228–236CrossRefPubMed

17.

Juniper EF, Guyatt GH, Jaeschke R (1996) How to develop and validate a new health-related quality of life instrument. In: Spilker B (ed) Quality of life and pharmacoeconomics in clinical trials, 2nd edn. Lippincott-Raven Publishers, Philadelphia, pp 49–56

18.

Martinez-Martin P, Rodriguez-Blazquez C, Abe K, Bhattacharyya KB, Bloem BR, Carod-Artal FJ, Prakesh R, Esselink RA, Falup-Pecurariu C, Gallardo M, Mir P, Naidu Y, Nicoletti A, Sethi K, Tsuboi Y, van Hilten JJ, Visser M, Zappia M, Chaudhuri KR (2009) International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease. Neurology 73:1584–1591CrossRefPubMed

19.

Middel B, van Sonderen E (2002) Statistical significant change vs. relevant or important change in (quasi) experimental design: some conceptual and methodological problems in estimating the magnitude of intervention-related change in health services research. Int J Integr Care 2:e15PubMedCentralPubMed

20.

Cohen J (1977) Statistical power analysis for the behavioral sciences, Rev edn. Academic Press, New York

21.

Deyo RA, Centor RM (1986) Assessing the responsiveness of functional scales to clinical change: an analogy to diagnostic test performance. J Chronic Dis 39:897–906CrossRefPubMed

22.

Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, Bouter LM, de Vet HC (2007) Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 60:34–42CrossRefPubMed

23.

McKhann G, Drachmann D, Folstein M, Katzman R, Price D, Stadlan EM (1984, 2013) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34:939–44

24.

Benke T, Andree B, Hittmair M, Gerstenbrand F (1990) Speech changes in dementia. Fortschr Neurol Psychiatr 58:215–223CrossRefPubMed

25.

Vink AC, Bruinsma MS, Scholten RJPM (2007) Music therapy for people with dementia (Review). Cochrane Reviews. http://www.bibliotecacochrane.com/pdf/CD003477.pdf. Accessed 15 Sept 2013

26.

Hall L, Orrell M, Stott J, Spector A (2012) Cognitive stimulation therapy (CST): neuropsychological mechanisms of change. Int Psychogeriatr 25:479–489CrossRefPubMed

27.

Reisberg B, Ferris SH, de Leon MJ, Crook T (1988) Global Deterioration Scale (GDS). Psychopharmacol Bull 24:661–663PubMed

28.

Schmidt R, Kienbacher E, Benke T, Dal-Bianco P, Delazer M, Ladurner G, Jellinger K, Ransmayer G, Schmidt H, Stögmann E, Friedrich J, Wehringer C (2008) Sex differences in Alzheimer’s disease. Neuropsychiatry 22:1–15

29.

Xing Y, Wei C, Chu C, Zhou A, Li P, Wu L, Song H, Zuo X, Wang F, Qin W, Li D, Tang Y, Jia XF, Jia J (2012) Stage-specific gender differences in cognitive and neuropsychiatric manifestations of vascular dementia. Am J Alzheimers Dis Other Demen 27:433–438CrossRefPubMed

30.

Bernick C, Cummings J, Raman R, Sun X, Aisen P (2012) Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch Neurol 69:901–905CrossRefPubMed

31.

Beckerman H, Roebroeck ME, Lankhorst GJ, Becher JG, Bezemer PD, Verbeek AL (2001) Smallest real difference, a link between reproducibility and responsiveness. Qual Life Res 10:571–578CrossRefPubMed

32.

Maheswaran H, Weich S, Powell J, Stewart-Brown S (2012) Evaluating the responsiveness of the Warwick Edinburgh Mental Well-Being Scale (WEMWBS): group and individual level analysis. Health Qual Life Outcomes 10:156PubMedCentralCrossRefPubMed

33.

Rapp MA, Schnaider-Beeri M, Schmeidler J, Sano M, Silverman JM, Haroutunian V (2005) Relationship of neuropsychological performance to functional status in nursing home residents and community-dwelling older adults. Am J Geriatr Psychiatry 13:450–459CrossRefPubMed

34.

Sikkes SAM, de Lange-de Klerk ESM, Pijnenburg YAL, Scheltens P, Uitdehaag BMJ (2009) A systematic review of instrumental activities of daily living scales in dementia: room for improvement. J Neurol Neurosurg Psychiatr 80:7–12CrossRefPubMed

35.

Ford GR, Haley WE, Thrower SL, West CA, Harrell LE (1996) Utility of Mini-Mental State Exam scores in predicting functional impairment among White and African American dementia patients. J Gerontol A Biol Sci Med Sci 51:M185–M188CrossRefPubMed

36.

Lehfield H, Erzigkeit H (2000) Loss of activities of daily living function (ADL) and cognitive impairment in various stages of dementia. A comparison of ADL informant ratings, ADL self ratings and psychometric test results. Fortschr Neurol Psychiatr 68:262–269CrossRef

37.

Juva K, Makela M, Erkinjuntti T, Sulkava R, Yukosi R, Valvanne J, Tilvis R (1997) Functional assessment scales in detecting dementia. Age Ageing 26:393–400CrossRefPubMed

38.

Galik E (2010) Function-focused care for LTC residents with moderate-to-severe dementia: a social ecological approach. Ann Longterm Care 18:27–32

Title: Validation of the multimodal assessment of capacities in severe dementia: a novel cognitive and functional scale for use in severe dementia
Authors: Sloane Heller
Carolina Mendoza Rebolledo
Carmen Rodríguez Blázquez
Laura Carrasco Chillón
Almudena Pérez Muñoz
Irene Rodríguez Pérez
Pablo Martínez-Martín
Publication date: 01-05-2015
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 5/2015
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-015-7692-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Validation of the multimodal assessment of capacities in severe dementia: a novel cognitive and functional scale for use in severe dementia

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2015

Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis

Redefining phenotypes associated with mitochondrial DNA single deletion

Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study

Erratum to: Respiratory dysfunction in Charcot–Marie–Tooth disease type 1A

Pitfalls in ataxia with ocular motor apraxia type 1: pseudodominant inheritance and very late onset

NEFL E396K mutation is associated with a novel dominant intermediate Charcot–Marie–Tooth disease phenotype